Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $57.10 million. The enterprise value is $109.76 million.
Important Dates
The next estimated earnings date is Friday, October 31, 2025, before market open.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 7.80 million shares outstanding. The number of shares has increased by 48.04% in one year.
| Current Share Class | 7.80M |
| Shares Outstanding | 7.80M |
| Shares Change (YoY) | +48.04% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 52.01% |
| Owned by Institutions (%) | 17.71% |
| Float | 3.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.72 |
| Forward PS | 0.59 |
| PB Ratio | 48.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 64.56.
| Current Ratio | 2.14 |
| Quick Ratio | 1.86 |
| Debt / Equity | 64.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.60 |
Financial Efficiency
Return on equity (ROE) is -219.68% and return on invested capital (ROIC) is -24.48%.
| Return on Equity (ROE) | -219.68% |
| Return on Assets (ROA) | -20.81% |
| Return on Invested Capital (ROIC) | -24.48% |
| Return on Capital Employed (ROCE) | -46.70% |
| Revenue Per Employee | $280,425 |
| Profits Per Employee | -$150,469 |
| Employee Count | 273 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 11.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.31% in the last 52 weeks. The beta is 0.98, so Biodesix's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -78.31% |
| 50-Day Moving Average | 8.08 |
| 200-Day Moving Average | 12.23 |
| Relative Strength Index (RSI) | 44.62 |
| Average Volume (20 Days) | 122,112 |
Short Selling Information
The latest short interest is 297,541, so 3.81% of the outstanding shares have been sold short.
| Short Interest | 297,541 |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 3.81% |
| Short % of Float | 9.20% |
| Short Ratio (days to cover) | 1.01 |
Income Statement
In the last 12 months, Biodesix had revenue of $76.56 million and -$41.08 million in losses. Loss per share was -$5.60.
| Revenue | 76.56M |
| Gross Profit | 60.30M |
| Operating Income | -33.89M |
| Pretax Income | -41.08M |
| Net Income | -41.08M |
| EBITDA | -28.08M |
| EBIT | -33.89M |
| Loss Per Share | -$5.60 |
Full Income StatementBalance Sheet
The company has $20.73 million in cash and $73.47 million in debt, giving a net cash position of -$52.74 million or -$6.76 per share.
| Cash & Cash Equivalents | 20.73M |
| Total Debt | 73.47M |
| Net Cash | -52.74M |
| Net Cash Per Share | -$6.76 |
| Equity (Book Value) | 1.14M |
| Book Value Per Share | 0.16 |
| Working Capital | 17.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.94 million and capital expenditures -$1.20 million, giving a free cash flow of -$31.13 million.
| Operating Cash Flow | -29.94M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -31.13M |
| FCF Per Share | -$3.99 |
Full Cash Flow StatementMargins
Gross margin is 78.77%, with operating and profit margins of -44.27% and -53.66%.
| Gross Margin | 78.77% |
| Operating Margin | -44.27% |
| Pretax Margin | -53.66% |
| Profit Margin | -53.66% |
| EBITDA Margin | -36.67% |
| EBIT Margin | -44.27% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.04% |
| Shareholder Yield | -48.04% |
| Earnings Yield | -72.04% |
| FCF Yield | -54.60% |
Analyst Forecast
The average price target for Biodesix is $32.50, which is 343.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.50 |
| Price Target Difference | 343.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biodesix has an Altman Z-Score of -6.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.75 |
| Piotroski F-Score | 3 |
